GERN
Geron Corporation
Biotechnology · Healthcare · United States
0.95
close · 2026-10-29
value
62
cheaper than peers62
quality
54
stronger fundamentals54
ranked against
Biotechnology (commercial)
value
quality
161 peerswide variation
Value inputs
| measure | company | vs peers |
| price to sales | 4.81× | 76 |
| price to book | 2.78× | 59 |
| forward P/E | 23.66× | 41 |
3 of 12 measures available
Quality inputs
| measure | company | vs peers |
| operating margin | -22.0% | 71 |
| return on equity | -28.3% | 67 |
| revenue growth | 17.2% | 49 |
| debt to equity | 55.9% | 29 |
4 of 4 measures available
Facts
| market cap | $608M |
| free cash flow | -$78.4M |
| employees | 258 |
| first trade | 1996-07-31 |
| next earnings | 2026-11-04 |
| fundamentals updated | 2026-08-18 |
Annual history
| measure | 2025 | 2024 | 2023 | 2022 |
| diluted eps | -0.13 | -0.27 | -0.32 | -0.37 |
| free cash flow | -$111.1M | -$219.3M | -$168.6M | -$127.8M |
| net income | -$83.5M | -$174.6M | -$184.1M | -$141.9M |
| revenue | $183.9M | $77.0M | $237,000 | $596,000 |
| unusual items | -$17.0M | -$1.7M | $0 | $0 |